Has Krupa Pandey, MD received payments from drug or device companies?

Yes. Drug and device makers reported $433,434 in general payments to Krupa Pandey, MD across 741 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Krupa Pandey, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Krupa Pandey, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Krupa Pandey, MD

Neurology · Albany, NYNPI 1255501508

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $318,883 of the $433,434 with a category attached, or 73.6%. 25 manufacturers reported payments, led by Biogen at 26.8% of the total. Among neurology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$433,434in general payments, 2019–2025

Across 741 payments — averaging $584.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Biogen$116K
Amgen$71K
Genentech USA, Inc.$68K
Sanofi$52K
E.r. Squibb & Sons, L.L.C.$46K
EMD Serono, Inc.$29K
plus $52K from 19 others

$3,339,028in research payments, 2019–2025

Across 242 payments — averaging $13,798 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Genentech, Inc.$1.8M
Novartis$816K
Sanofi$250K
E.r. Squibb & Sons, L.L.C.$241K
Bristol Myers Squibb$104K
Biogen$51K
plus $91K from 4 others

What the payments were for

Consulting fees$85,43220%
Speaking & faculty fees$318,88374%
Travel & lodging$13,4933%
Food & beverage$15,2394%
Education$3880%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Biogen	103	$115,989
Amgen(2 entities)	103	$70,690
Genentech USA, Inc.	85	$68,018
Sanofi	40	$51,723
E.r. Squibb & Sons, L.L.C.	32	$45,577
EMD Serono, Inc.	79	$29,318
AstraZeneca	37	$23,689
Bristol Myers Squibb	90	$21,017
TG Therapeutics, Inc.	5	$3,946
Novartis	98	$2,115
Teva Pharmaceuticals USA, Inc.	14	$222
Johnson & Johnson	19	$217
Genentech, Inc.	3	$213
AbbVie(2 entities)	11	$168
Lilly USA, LLC	11	$164
SK Life Science, Inc.	1	$147
Biohaven Pharmaceuticals, Inc.	1	$75
Lundbeck LLC	2	$31
Philips North America LLC	1	$21
Neurocrine Biosciences, Inc.	1	$17
Mallinckrodt Enterprises LLC	1	$16
Merz Pharmaceuticals, LLC	1	$16
Mallinckrodt Hospital Products Inc.	1	$16
Bausch Health US, LLC	1	$15
Avanir Pharmaceuticals, Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

UPLIZNA$52,405
Vumerity$47,429
ZEPOSIA$44,174
OCREVUS$41,716
AUBAGIO$31,257
TYSABRI$26,876
Mavenclad$17,078
SOLIRIS$11,236
TECFIDERA$8,780
BRIUMVI$3,832
AVONEX$2,480
PLEGRIDY$2,480

How this compares

$433,434 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York →

Medicare billing

Part B allowed, 2024

$24,998

Medicare patients

Services billed

191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Kesimpta PenOfatumumab	48	$452,777
AmpyraDalfampridine	12	$57,617
Glatiramer Acetate	15	$30,975
Dalfampridine ErDalfampridine	39	$13,449
Baclofen	64	$1,843
Teriflunomide	14	$626
Gabapentin	17	$361
Amitriptyline Hcl	12	$210

Paid to pharmacies, not to this prescriber.

Other neurology in Albany

Charles ArgoffAlbany$1.2M
Stanley PencAlbany$657K
Angela ApplebeeAlbany$537K
Timothy LynchAlbany$265K
Idan SharonBrooklyn$2.1M
Allan PerelStaten Island$1.7M
Nicolas SaikaliAmherst$1.5M
David KreitzmanCommack$1.5M
Stephen KriegerNew York$1.1M
Robert FeketeHawthorne$1M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →